Prognostic value of serum interleukin-6 (IL-6) levels in long term care

Maurel, Stéphane; Hamon, Brigitte; Taillandier, J; Rudant, E.; Bonhomme-Faivre, Laurence; Trivalle, C.

doi:10.1016/j.archger.2006.09.003

Cited by 7 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, it is important to recall that, both before and after body weight correction, IL-6 levels are positively associated with age in women and MDA in men (only before body weight correction), respectively, suggesting and confirming that age/menopause status and ageing behave differently in women and men. The increase in IL-6 levels and its correlation with age are in line with the data found in the literature 8 , 9 , 27 , 28 , even if some other authors did not find it 29 , 30 . Here, the increase in IL-6 is not accompanied by a TNF-α increase, which, on the contrary, tends to be higher in premenopausal women than in postmenopausal women, both before and after body correction.…”

Section: Discussionsupporting

confidence: 91%

Ageing/Menopausal Status in Healthy Women and Ageing in Healthy Men Differently Affect Cardiometabolic Parameters

Campesi¹,

Occhioni²,

Tonolo

et al. 2016

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: Gender medicine requires a global analysis of an individual's life. Menopause and ageing induce variations of some cardiometabolic parameters, but, it is unknown if this occurs in a sex-specific manner. Here, some markers of oxidative stress, systemic inflammation, and endothelial dysfunction are analysed in men younger and older than 45 years and in pre- and postmenopausal women.Methods: Serum and plasma sample were assayed for TNF-α and IL-6, malondialdehyde and protein carbonyls and for methylated arginines using ELISA kits, colorimetric methods and capillary electrophoresis.Results: Before body weight correction, men overall had higher creatinine, red blood cells and haemoglobin and lower triglycerides than women. Men younger than 45 years had lower levels of TNF-α and malondialdehyde and higher levels of arginine than age-matched women, while postmenopausal women had higher IL-6 concentrations than men, and higher total cholesterol, triglycerides, creatinine and IL-6 levels than younger women. Men younger than 45 years had lower total cholesterol and malondialdehyde than older men. After correction, some differences remained, others were amplified, others disappeared and some new differences emerged. Moreover, some parameters showed a correlation with age, and some of them correlated with each other as functions of ageing and ageing/menopausal status.Conclusions: Ageing/menopausal status increased many more cardiovascular risk factors in women than ageing in men, confirming that postmenopausal women had increased vascular vulnerability and indicating the need of early cardiovascular prevention in women. Sex-gender differences are also influenced by body weight, indicating as a matter of debate whether body weight should be seen as a true confounder or as part of the causal pathway.

show abstract

Section: Discussionsupporting

confidence: 91%

Ageing/Menopausal Status in Healthy Women and Ageing in Healthy Men Differently Affect Cardiometabolic Parameters

Campesi¹,

Occhioni²,

Tonolo

et al. 2016

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…The mean IL-6 concentration was 5.99 and 9.9 pg/mL for the men and the women, respectively. In that study, IL-6 levels of at least 3 pg/mL in men and 5.6 pg/mL in women were associated with a significantly higher risk of death [16]. In our series, all COVID-19 patients but one had IL-6 levels higher than 5 pg/mL.…”

Section: Discussionsupporting

confidence: 45%

“…According to Robak et al [15], the median IL-6 level in normal subjects is 5.3 pg/mL (0.5-16.6). Maurel et al [16] evaluated IL-6 concentrations in a simi-lar geriatric population from long-term care facilities (184 females and 65 males). At baseline, IL-6 was quantifiable (≥3 pg/mL) in only 35% of the evaluated subjects.…”

Section: Discussionmentioning

confidence: 99%

Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19

Diaz¹,

Ramos-Suzarte

Martin³

et al. 2020

Gerontology

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of coronavirus disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11, 2020. Elderly individuals with multiple comorbidities are particularly susceptible to adverse clinical outcomes in the course of SARS-CoV-2 infection. During the outbreak, a local transmission event took place in a nursing home in Villa Clara province, Cuba, in which 19 elderly residents tested positive for SARS-CoV-2. Methods: Based on the increased susceptibility to cytokine release syndrome, inducing respiratory and systemic complications in this population, 19 patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody. Results: All patients had underlying medical conditions. The product was well tolerated. After the first dose, the course of the disease was favorable, and 18 of the 19 patients (94.7%) were discharged clinically recovered with negative real-time reverse transcription polymerase chain reaction test results at 13 days. After one dose of itolizumab, circulating IL-6 decreased within the first 24–48 h in patients with high baseline values, whereas in patients with low levels, this concentration remained over low values. To preliminarily assess the effect of itolizumab, a control group was selected among the Cuban COVID-19 patients that did not receive immunomodulatory therapy. The control subjects were well matched regarding age, comorbidities, and severity of the disease. The percentage of itolizumab-treated, moderately ill patients who needed to be admitted to the intensive care unit was only one-third of that of the control group not treated with itolizumab. Additionally, treatment with itolizumab reduced the risk of death 10 times as compared with the control group. Conclusion: This study corroborates that the timely use of itolizumab in combination with other antivirals reduces COVID-19 disease worsening and mortality. The humanized antibody itolizumab emerges as a therapeutic alternative for patients with COVID-19. Our results suggest the possible use of itolizumab in patients with cytokine release syndrome from other pathologies.

show abstract

“…Interestingly, a further elevation of IL-6 concentrations has been reported in very old people (Akbaraly et al, 2013;Bermejo-Martin et al, 2020;Puzianowska-Kuźnicka et al, 2016). Moreover, although authors reported contrasting data, a wealth of studies support the potential correlation of IL-6 levels with aging and chronic morbidity (Maurel et al, 2007;Puzianowska-Kuźnicka et al, 2016). Experimental conditions, stratification parameters and the medical health screening of enrolled subjects may explain contradicting results (Alley et al, 2008;Ferrucci et al, 2005).…”

Section: Skeletal Muscle As a Source And A Physio-pathologic Target O...mentioning

confidence: 99%

The hormetic and hermetic role of IL-6

Forcina

Franceschi²,

Musarò³

2022

Ageing Research Reviews

View full text Add to dashboard Cite

Prognostic value of serum interleukin-6 (IL-6) levels in long term care

Cited by 7 publications

References 18 publications

Ageing/Menopausal Status in Healthy Women and Ageing in Healthy Men Differently Affect Cardiometabolic Parameters

Ageing/Menopausal Status in Healthy Women and Ageing in Healthy Men Differently Affect Cardiometabolic Parameters

Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19

The hormetic and hermetic role of IL-6

Contact Info

Product

Resources

About